Compare
Lisata Therapeutics, Inc. vs Serina Therapeutics, Inc. vs Vyome Holdings, Inc vs Allarity Therapeutics, Inc.
| Latest fiscal year | Lisata Therapeutics, Inc. LSTA | Serina Therapeutics, Inc. SER | Vyome Holdings, Inc HIND | Allarity Therapeutics, Inc. ALLR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $170.0K | $130.0K | $319.7K | $320.0K |
| Revenue growth (YoY) | -83.0% | +132.1% | +24.4% | n/a |
| Gross margin | n/a | n/a | 68.4% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$16.59M | -$19.18M | -$10.26M | -$11.23M |
| EPS (Diluted) | -$1.91 | -$1.91 | -$4.86 | n/a |
| Operating cash flow | -$15.95M | -$17.95M | -$3.75M | -$14.82M |
| Free cash flow | -$15.98M | -$18.01M | n/a | -$14.83M |
| Cash & equivalents | $15.96M | $3.06M | $4.98M | $14.69M |
| Total assets | $17.74M | $6.95M | $6.50M | $18.26M |
| Total liabilities | $3.14M | $6.99M | $2.74M | $8.43M |
| Shareholders' equity | $14.86M | -$37.0K | $3.76M | $9.83M |
| Return on year-end equity | -111.7% | n/a | -272.8% | -114.3% |
| Shares outstanding | 8.83M | 10.77M | 5.92M | 16.08M |
Revenue, most recent five fiscal years
| Fiscal year | Lisata Therapeutics, Inc. | Serina Therapeutics, Inc. | Vyome Holdings, Inc | Allarity Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $170.0K Ended 2025-12-31 | $130.0K Ended 2025-12-31 | $319.7K Ended 2025-12-31 | $320.0K Ended 2025-12-31 |
| 1 year earlier | $1.00M Ended 2024-12-31 | $56.0K Ended 2024-12-31 | $256.9K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $3.15M Ended 2023-12-31 | $8.68M Ended 2023-12-31 | n/a |
| 3 years earlier | $0 Ended 2022-12-31 | $34.0K Ended 2022-12-31 | $11.24M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $144.0K Ended 2021-12-31 | $13.60M Ended 2021-12-31 | n/a |